BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 34030695)

  • 1. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
    Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
    Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France.
    Cottin V; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Jouneau S; Hachulla E; Chollet J; Nasser M
    Front Med (Lausanne); 2021; 8():699532. PubMed ID: 34552943
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
    Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
    Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI; Park H; Park S; Shin JY; Kim YH
    BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 10. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [No Abstract]   [Full Text] [Related]  

  • 11. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
    Raimundo K; Solomon JJ; Olson AL; Kong AM; Cole AL; Fischer A; Swigris JJ
    J Rheumatol; 2019 Apr; 46(4):360-369. PubMed ID: 30442831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
    J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
    Adegunsoye A; Oldham JM; Bellam SK; Montner S; Churpek MM; Noth I; Vij R; Strek ME; Chung JH
    Ann Am Thorac Soc; 2019 May; 16(5):580-588. PubMed ID: 30653927
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
    Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
    Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies.
    Shao C; Xia N; Zhen Y; Zhang X; Yan N; Guo Q
    Front Immunol; 2024; 15():1404828. PubMed ID: 38745647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach.
    Wuyts WA; Papiris S; Manali E; Kilpeläinen M; Davidsen JR; Miedema J; Robalo-Cordeiro C; Morais A; Artés M; Asijee G; Cendoya D; Soulard S
    Adv Ther; 2020 Jul; 37(7):3246-3264. PubMed ID: 32445186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care.
    Frank AL; Kreuter M; Schwarzkopf L
    Respir Med; 2019 Jun; 152():25-31. PubMed ID: 31128606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Burden of Progressive-Fibrosing Interstitial Lung Diseases.
    Cottin V; Teague R; Nicholson L; Langham S; Baldwin M
    Front Med (Lausanne); 2022; 9():799912. PubMed ID: 35178411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.